AskBio 009

Drug Profile

AskBio 009

Alternative Names: Adeno-associated virus serotype 8 Factor IX gene therapy; AskBio-009; BAX 335; FIX gene therapy

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Asklepios BioPharmaceutical
  • Developer Asklepios BioPharmaceutical; Baxter International
  • Class Gene therapies
  • Mechanism of Action Factor IX stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 22 Sep 2015 Phase-I/II development for Haemophilia B is ongoing in USA (NCT01687608)
  • 24 Jun 2015 Phase I/II development is ongoing in USA
  • 24 Jun 2015 Efficacy data from a phase I/II trial in Haemophilia B released by Baxalta
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top